Literature DB >> 22585167

ATM mutations in patients with hereditary pancreatic cancer.

Nicholas J Roberts1, Yuchen Jiao, Jun Yu, Levy Kopelovich, Gloria M Petersen, Melissa L Bondy, Steven Gallinger, Ann G Schwartz, Sapna Syngal, Michele L Cote, Jennifer Axilbund, Richard Schulick, Syed Z Ali, James R Eshleman, Victor E Velculescu, Michael Goggins, Bert Vogelstein, Nickolas Papadopoulos, Ralph H Hruban, Kenneth W Kinzler, Alison P Klein.   

Abstract

UNLABELLED: Pancreatic cancers are the fourth most-common cause of cancer-related deaths in the Western world, with >200,000 cases reported in 2010. Although up to 10% of these cases occur in familial patterns, the hereditary basis for predisposition in the vast majority of affected families is unknown. We used next-generation sequencing, including whole-genome and whole-exome analyses, and identified heterozygous, constitutional, ataxia telangiectasia mutated (ATM) gene mutations in 2 kindreds with familial pancreatic cancer. Mutations segregated with disease in both kindreds and tumor analysis demonstrated LOH of the wild-type allele. By using sequence analysis of an additional 166 familial pancreatic cancer probands, we identified 4 additional patients with deleterious mutations in the ATM gene, whereas we identified no deleterious mutations in 190 spouse controls (P = 0.046). When we considered only the mostly severely affected families with 3 or more pancreatic cancer cases, 4 deleterious mutations were found in 87 families (P = 0.009). Our results indicate that inherited ATM mutations play an important role in familial pancreatic cancer predisposition. SIGNIFICANCE: The genes responsible for the majority of cases of familial pancreatic ductal adenocarcinoma are unknown. We here identify ATM as a predisposition gene for pancreatic ductal adenocarcinoma. Our results have important implications for the management of patients in affected families and illustrate the power of genome-wide sequencing to identify the basis of familial cancer syndromes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22585167      PMCID: PMC3676748          DOI: 10.1158/2159-8290.CD-11-0194

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  26 in total

1.  Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening.

Authors:  M Telatar; Z Wang; N Udar; T Liang; E Bernatowska-Matuszkiewicz; M Lavin; Y Shiloh; P Concannon; R A Good; R A Gatti
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  Cancer risk in heterozygotes for ataxia-telangiectasia.

Authors:  B Geoffroy-Perez; N Janin; K Ossian; A Laugé; M F Croquette; C Griscelli; M Debré; B Bressac-de-Paillerets; A Aurias; D Stoppa-Lyonnet; N Andrieu
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

3.  Heterozygous ATM mutations do not contribute to early onset of breast cancer.

Authors:  M G FitzGerald; J M Bean; S R Hegde; H Unsal; D J MacDonald; D P Harkin; D M Finkelstein; K J Isselbacher; D A Haber
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

4.  Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients.

Authors:  A Li; M Swift
Journal:  Am J Med Genet       Date:  2000-05-29

5.  Mutations associated with variant phenotypes in ataxia-telangiectasia.

Authors:  C M McConville; T Stankovic; P J Byrd; G M McGuire; Q Y Yao; G G Lennox; M R Taylor
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer.

Authors:  P Athma; R Rappaport; M Swift
Journal:  Cancer Genet Cytogenet       Date:  1996-12

7.  Malignant neoplasms in the families of patients with ataxia-telangiectasia.

Authors:  M Swift; L Sholman; M Perry; C Chase
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

8.  Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss.

Authors:  Christine A Iacobuzio-Donahue; Michiel S van der Heijden; Mark R Baumgartner; William J Troup; Jane M Romm; Kimberly Doheny; Elizabeth Pugh; Charles J Yeo; Michael G Goggins; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

9.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

10.  Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries.

Authors:  V Corbo; S Beghelli; S Bersani; D Antonello; G Talamini; M Brunelli; P Capelli; M Falconi; A Scarpa
Journal:  Ann Oncol       Date:  2011-03-29       Impact factor: 32.976

View more
  200 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer.

Authors:  Seung-Mo Hong; Audrey Vincent; Mitsuro Kanda; Julie Leclerc; Noriyuki Omura; Michael Borges; Alison P Klein; Marcia Irene Canto; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

Review 3.  Pancreatic Cancer Surveillance: Who, When, and How.

Authors:  Beth Dudley; Randall E Brand
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 4.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 5.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

Review 6.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

7.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

Review 8.  Identifying people at a high risk of developing pancreatic cancer.

Authors:  Alison P Klein
Journal:  Nat Rev Cancer       Date:  2012-12-06       Impact factor: 60.716

Review 9.  Risk of pancreatic cancer in breast cancer families from the breast cancer family registry.

Authors:  Evelina Mocci; Roger L Milne; Elena Yuste Méndez-Villamil; John L Hopper; Esther M John; Irene L Andrulis; Wendy K Chung; Mary Daly; Saundra S Buys; Nuria Malats; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-01       Impact factor: 4.254

Review 10.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.